Lakewood-Amedex Biotherapeutics redeems Series C preferred stock for $1,270,970
LABT•Lakewood-Amedex Biotherapeutics redeemed 127,097 shares of Series C Convertible Preferred Stock for $1.27 million using cash on hand. No preferred stock or indebtedness for borrowed money remains outstanding.
1. Redemption completed
Lakewood-Amedex Biotherapeutics completed the redemption under a November 2, 2026, agreement with Shakawe Capital. The company said the redemption eliminates potential conversion dilution and associated financing restrictions.
